Quick Answer
Sionna Therapeutics, Inc. reported Operating Income Loss of -$88.98 million for the year ending 2025.
- Sionna Therapeutics, Inc. showed a decrease of -26.1% in Operating Income Loss from 2024 to 2025.
- This data is from Sionna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$13.15 million | Q2 2024: -$11.29 million | Q3 2024: -$27.98 million | Q1 2025: -$19.66 million | Q2 2025: -$21.91 million | Q3 2025: -$23.81 million.
- Historical annual values: Fiscal year 2025: -$88.98 million | Fiscal year 2024: -$70.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: